Literature DB >> 16283593

Adenylyl cyclase type V deletion increases basal left ventricular function and reduces left ventricular contractile responsiveness to beta-adrenergic stimulation.

Tong Tang1, N Chin Lai, David M Roth, Jeffrey Drumm, Tracy Guo, Ko-Woon Lee, Pyung-Lim Han, Nancy Dalton, Mei Hua Gao.   

Abstract

We tested the hypothesis that deletion of adenylyl cyclase type V (AC(V)) would be associated with decreased left ventricular (LV) contractile function and responsiveness to beta-adrenergic receptor (betaAR) stimulation. Absence of cardiac AC(V) expression was confirmed by RT-PCR and immunoblotting in AC(V)-deleted mice (AC(V) (-/-)). Compared to sibling mice with normal amounts of AC(V) (CON), basal and water-soluble forskolin derivative NKH477-stimulated cAMP production was reduced in both LV homogenates and in isolated cardiac myocytes. Basal LV +dP/dt (isolated perfused hearts) was increased (CON: 3,649 +/- 247 mmHg/s; AC(V) (-/-): 4,625 +/- 350 mmHg/s; p = 0.035, n = 10), but the potency of dobutamine on LV +dP/dt was decreased by AC(V) deletion (log EC(50): CON: -6.83 +/- 0.14 M; AC(V) (-/-): -5.99 +/- 0.15 M; p = 0.0007, n = 10). The initial rates of ATP-dependent sarcoplasmic reticulum calcium uptake, assessed in LV homogenates, showed that AC(V) deletion increased SERCA2a affinity for Ca(2+) (log EC(50): CON: -5.94 +/- 0.03 M; AC(V) (-/-): -6.09 +/- 0.02 M; p = 0.001, n = 8). AC(V) deletion is also associated with increased phospholamban phosphorylation, decreased type 1 protein phosphatase catalytic subunit content and activity, and reduced cardiac Galphas protein content. In conclusion, AC(V) deletion has a favorable effect on basal LV function despite reduced cAMP levels. Increased SERCA2a affinity for Ca(2+) and increased phospholamban phosphorylation are contributing factors. However, AC(V) deletion is associated with reduced LV contractile responsiveness to betaAR stimulation, an effect that is associated with reduced Galphas protein content and reduced cAMP generating capacity in cardiac myocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283593     DOI: 10.1007/s00395-005-0559-y

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  19 in total

Review 1.  Prospects for gene transfer for clinical heart failure.

Authors:  T Tang; M H Gao; H Kirk Hammond
Journal:  Gene Ther       Date:  2012-04-26       Impact factor: 5.250

2.  Type 5 adenylyl cyclase plays a major role in stabilizing heart rate in response to microgravity induced by parabolic flight.

Authors:  Satoshi Okumura; Takashi Tsunematsu; Yunzhe Bai; Qibin Jiao; Shinji Ono; Sayaka Suzuki; Reiko Kurotani; Motohiko Sato; Susumu Minamisawa; Satoshi Umemura; Yoshihiro Ishikawa
Journal:  J Appl Physiol (1985)       Date:  2008-05-01

Review 3.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

Review 4.  Unanticipated signaling events associated with cardiac adenylyl cyclase gene transfer.

Authors:  Mei Hua Gao; H Kirk Hammond
Journal:  J Mol Cell Cardiol       Date:  2011-02-23       Impact factor: 5.000

5.  Disruption of adenylyl cyclase type V does not rescue the phenotype of cardiac-specific overexpression of Galphaq protein-induced cardiomyopathy.

Authors:  Valeriy Timofeyev; Cliff A Porter; Dipika Tuteja; Hong Qiu; Ning Li; Tong Tang; Anil Singapuri; Pyung-Lim Han; Javier E Lopez; H Kirk Hammond; Nipavan Chiamvimonvat
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-13       Impact factor: 4.733

Review 6.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 7.  Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies.

Authors:  Rachna Sadana; Carmen W Dessauer
Journal:  Neurosignals       Date:  2008-10-24

8.  Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses.

Authors:  Satoshi Okumura; Takayuki Fujita; Wenqian Cai; Meihua Jin; Iyuki Namekata; Yasumasa Mototani; Huiling Jin; Yoshiki Ohnuki; Yayoi Tsuneoka; Reiko Kurotani; Kenji Suita; Yuko Kawakami; Shogo Hamaguchi; Takaya Abe; Hiroshi Kiyonari; Takashi Tsunematsu; Yunzhe Bai; Sayaka Suzuki; Yuko Hidaka; Masanari Umemura; Yasuhiro Ichikawa; Utako Yokoyama; Motohiko Sato; Fumio Ishikawa; Hiroko Izumi-Nakaseko; Satomi Adachi-Akahane; Hikaru Tanaka; Yoshihiro Ishikawa
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

Review 9.  Capturing adenylyl cyclases as potential drug targets.

Authors:  Sandra Pierre; Thomas Eschenhagen; Gerd Geisslinger; Klaus Scholich
Journal:  Nat Rev Drug Discov       Date:  2009-04       Impact factor: 84.694

Review 10.  New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy.

Authors:  Huy M Phan; Mei Hua Gao; N Chin Lai; Tong Tang; H Kirk Hammond
Journal:  Trends Cardiovasc Med       Date:  2007-10       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.